Biogen Idec, Alnylam to Team on PML Drug
Posted on: Wednesday, 20 September 2006, 18:01 CDT
U.S. firms Biogen Idec and Alnylam said Wednesday they have signed a deal on a drug for progressive multifocal leukoencephalopathy.
The condition is marked by an infection of the central nervous system caused by the JC virus, the companies said.
The deal provides for Alnylam and Biogen Idec to collaborate on research into PML therapies using RNAi technology.
Under the terms of the agreement, Biogen Idec will fund all research and development and Alnylam will receive an upfront payment of $5 million, with any resulting products triggering additional payments to Alnylam of more than $51 million.
This innovative collaboration to explore using RNAi technology to develop therapeutics for the treatment of PML will build on our work to understand and manage this disease, said Al Sandrock, Biogen Idec's senior vice president of neurology. We are pleased to partner with Alnylam, a company that has demonstrated leading capabilities in the discovery and development of RNAi therapeutics, in this important undertaking.
Source: United Press International
Related Articles
- Alnylam and Collaborators Publish In Vivo Research on Validation of a Mammalian Host Gene Involved in Malaria Infection and on the Anti-Parasitic Efficacy of RNAi Therapeutics
- Alnylam Presents Pre-Clinical Data From Hypercholesterolemia, Liver Cancer, Ebola, and Progressive Multifocal Leukoencephalopathy (PML) Programs at RNAi Keystone Symposium
- Alnylam Achieves First Human Proof of Concept for an RNAi Therapeutic With GEMINI Study
- Alnylam Reports Pre-Clinical Progress With RNAi Therapeutics in Neurological Disease
- Alnylam Reports Positive Phase II Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
- Alnylam Launches Its RNAi 2010 Outlook for Key Scientific, Clinical, and Business Initiatives; Announces Goals and Guidance for 2008
- Biogen Idec and Alnylam Form Alliance to Discover and Develop Therapeutics for the Potential Treatment of Progressive Multifocal Leukoencephalopathy (PML); Collaboration to Focus on RNAi Therapeutics Targeting the JC Virus
- Novartis and Alnylam to Develop RNAi Therapeutics for Pandemic Flu
- Alnylam Pharmaceuticals Initiates RNAi Therapeutic Development Program for Respiratory Syncytial Virus Infection
 |
 |
User Comments (1)
| 1. |
Posted by David Penkala on 01/17/2007, 13:53 It's about time someone is going to look into and feel responsible for the treatment therapy needed for PML. |
RSS Feeds